We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Becton Dickinson and Company | NYSE:BDX | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.05 | 0.44% | 238.00 | 275 | 12:54:22 |
From May 2019 to May 2024
By Matt Grossman
Becton Dickinson & Co. is planning to spin off its diabetes-care business as an independent, publicly traded company.
The Franklin Lakes, N.J.-based medical-technology company said Thursday that the spinoff will take place in the first half of next year, and will be accomplished via a distribution of stock in the new company to Becton Dickinson shareholders.
The new company will be led by Devdatt Kurdikar as chief executive. Mr. Kurdikar is currently the world-wide president of Becton Dickinson's diabetes-care division.
Becton Dickinson Chairman and Chief Executive Officer Tom Polen said that the spinoff will allow Becton Dickinson to place a greater investment focus on other core businesses.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
May 06, 2021 06:39 ET (10:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Becton Dickinson Chart |
1 Month Becton Dickinson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
